

1 **Diagnostic Accuracy of the Abbot BinaxNOW COVID-19 Antigen Card Test, Puerto Rico**

2
3 Zachary J. Madewell¹, Chelsea G. Major¹, Nathan Graff², Cameron Adams³, Dania M. Rodriguez¹,
4 Tatiana Morales⁴, Nicole A. Medina Lopes¹, Rafael Tosado¹, Liliana Sánchez-González¹, Janice Perez-
5 Padilla¹, Hannah R. Volkman¹, Jorge Bertran⁵, Diego Sainz⁵, Jorge Munoz-Jordan¹, Gilberto A.
6 Santiago¹, Olga Lorenzi¹, Vanessa Rivera-Amill⁴, Melissa A. Rolfes⁶, Gabriela Paz-Bailey¹, Laura E.
7 Adams¹, Joshua M. Wong¹, PRESCA Study Team

8

9 **Affiliations**

- 10 1. Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan, Puerto Rico
- 11 Rico
- 12 2. Eagle Health Analytics, San Antonio, Texas, USA
- 13 3. Department of Microbiology and Immunology, University of North Carolina School of Medicine,
- 14 Chapel Hill, North Carolina, USA
- 15 4. Ponce Health Sciences University/Ponce Research Institute, Ponce, Puerto Rico
- 16 5. Auxilio Mutuo Hospital, San Juan, Puerto Rico
- 17 6. Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA

18

19 **Corresponding author:** Zachary J. Madewell

20 **Corresponding author email:** ock0@cdc.gov

21

22 **Running title:** Abbot BinaxNOW COVID-19 Antigen Card test

23 **Data availability:** Due to data security and confidentiality guidelines, all analyses, and restricted-use
24 datasets, including questionnaire forms and code, must be requested from CDC and PMFS after
25 submitting a concept proposal to dengue@cdc.gov.

26 **Funding:** This work was supported by the National Center for Emerging and Zoonotic Infectious
27 Diseases and the Center for State, Tribal, Local, and Territorial Support at the Centers for Disease Control
28 and Prevention [grant numbers U01CK000437 and U01CK000580 to V.R.A.]. The funders had no role in
29 study design, data collection and analysis, decision to publish, or preparation of the manuscript.

30 <https://www.cdc.gov/ncezid/index.html> [https://www.cdc.gov/publichealthgateway/about-](https://www.cdc.gov/publichealthgateway/about-cstlts/index.html)
31 [cstlts/index.html](https://www.cdc.gov/publichealthgateway/about-cstlts/index.html).

32 **Conflict of interest:** The authors declare no conflict of interests.

33 **Ethics approval and consent to participate:** Approval for the COPA project was obtained from the
34 Ponce Medical School Foundation, Inc. Institutional Review Board (protocol number 171110-VR). The
35 Institutional Review Boards at the CDC, Auxilio Mutuo, and Ponce Medical School Foundation approved
36 the SEDSS study protocols 6214, and 120308-VR, respectively. Written consent to participate was
37 obtained from all adult participants and emancipated minors; parental written consent and participant
38 assent were obtained for children.

39 **Disclaimer:** The findings and conclusions in this report are those of the authors and do not necessarily
40 represent the official position of the US Centers for Disease Control and Prevention.

41 **Abstract**

42 **Background:** The COVID-19 pandemic underscored the need for rapid and accurate diagnostic tools. In
43 August 2020, the Abbot BinaxNOW COVID-19 Antigen Card test became available as a timely and
44 affordable alternative for SARS-CoV-2 molecular testing, but its performance may vary due to factors
45 including timing and symptomatology. This study evaluates BinaxNOW diagnostic performance in
46 diverse epidemiological contexts.

47 **Methods:** Using RT-PCR as reference, we assessed performance of the BinaxNOW COVID-19 test for
48 SARS-CoV-2 detection in anterior nasal swabs from participants of two studies in Puerto Rico from
49 December 2020 to May 2023. Test performance was assessed by days post symptom onset, collection
50 strategy, vaccination status, symptomatology, repeated testing, and RT-PCR cycle threshold (Ct) values.

51 **Results:** BinaxNOW demonstrated an overall sensitivity of 84.1% and specificity of 98.8%. Sensitivity
52 peaked within 1–6 days after symptom onset (93.2%) and was higher for symptomatic (86.3%) than
53 asymptomatic (67.3%) participants. Sensitivity declined over the course of infection, dropping from
54 96.3% in the initial test to 48.4% in testing performed 7–14 days later. BinaxNOW showed 99.5%
55 sensitivity in participants with low Ct values (≤ 25) but lower sensitivity (18.2%) for participants with
56 higher Cts (36–40).

57 **Conclusions:** BinaxNOW demonstrated high sensitivity and specificity, particularly in early-stage
58 infections and symptomatic participants. In situations where test sensitivity is crucial for clinical decision-
59 making, nucleic acid amplification tests are preferred. These findings highlight the importance of
60 considering clinical and epidemiological context when interpreting test results and emphasize the need for
61 ongoing research to adapt testing strategies to emerging SARS-CoV-2 variants.

62

63 **Keywords:** Rapid Antigen Test; Omicron; Diagnostic Accuracy; Puerto Rico; Sensitivity; SARS-CoV-2

64 **Introduction**

65 As of October 2023, the COVID-19 pandemic has led to 771 million confirmed cases of COVID-
66 19 and 7 million deaths globally, with Puerto Rico reporting almost 1.3 million COVID-19 cases and
67 6,000 associated deaths.¹ Rapid identification of SARS-CoV-2 infection and subsequent measures to
68 reduce transmission are central to an effective public health response to COVID-19.² However, the broad
69 spectrum of clinical manifestations of SARS-CoV-2 infection poses a challenge to the rapid identification
70 of infections and the implementation of effective measures to reduce transmission.²⁻⁴ Concurrently, the
71 pandemic prompted the development of novel therapies⁵⁻⁸ that are designed to shorten COVID-19
72 symptom duration. Early identification of SARS-CoV-2 infection is crucial for the timely and appropriate
73 administration of therapies, particularly for people at higher risk for severe disease. Many of the novel
74 treatments developed during the pandemic require initiation within a specific window after symptom
75 onset. However, the challenges posed by the broad spectrum of clinical manifestations, including initially
76 asymptomatic and mild cases that can progress to severe disease, make early and accurate detection of
77 SARS-CoV-2 infection essential for effective treatment and prevention strategies.

78 To identify infected individuals for isolation and appropriate medical therapy, rapid and accurate
79 COVID-19 tests continue to play a crucial role, including those used in clinical and laboratory settings.
80 Although RT-PCR-based testing is frequently available in clinical and laboratory settings for infection
81 detection, its utility can be limited by the expertise required for proper sample management and reporting
82 delays due to the time needed for transport and testing at laboratory facilities.^{9,10} In many communities,
83 point-of-care rapid antigen tests were deployed to enhance the accessibility and efficiency of SARS-CoV-
84 2 infection detection. Among the available commercial lateral flow antigen tests, the BinaxNOW Antigen
85 Card test has undergone particularly extensive evaluation, demonstrating consistent specificity (>97%)
86 across multiple cohort studies.¹¹⁻¹⁵ However, sensitivity estimates varied widely in different reports, with
87 potential factors including timing of specimen collection, symptom presence, collection methodology, and
88 viral replication levels, necessitating further validation.

89 In December 2020, BinaxNOW testing was introduced alongside RT-PCR testing for SARS-
90 CoV-2 in a community cohort and two clinical surveillance sites in Puerto Rico. We evaluated how the
91 performance of BinaxNOW varied by days post onset of symptoms, symptomatology, predominant
92 SARS-CoV-2 variant, vaccination status, collection strategy, repeated tests, and RT-PCR cycle thresholds
93 (Ct). This study leverages its large sample size, including specimens collected at various time points from
94 a unique population in Puerto Rico, to provide a comprehensive evaluation of the BinaxNOW Antigen
95 Card test's performance, contributing to filling an information gap in the use of point-of-care rapid
96 antigen tests for SARS-CoV-2 infection detection. Our findings contribute to a deeper understanding of
97 the test's efficacy and role in augmenting current diagnostic strategies.

98

99 **Methods**

100 *Study Design and Data Collection*

101 The data analyzed is derived from two observational studies in Puerto Rico: the Communities
102 Organized to Prevent Arboviruses (COPA) study and the Sentinel Enhanced Dengue Surveillance System
103 (SEDSS), both of which are conducted by the Ponce Health Sciences University (PHSU) and the US
104 Centers for Disease Control and Prevention's (CDC) Dengue Branch (DB).

105 COPA is a community-based cohort study established in Ponce, Puerto Rico, in 2018. Study
106 enrollment and data collection activities are described elsewhere.¹⁶⁻¹⁸ Briefly, study activities include
107 annual interviews and serum collection for arbovirus testing among approximately 3,800 participants.
108 Beginning in April 2020, anterior nasal swabs for SARS-CoV-2 RT-PCR testing were collected from
109 participants that reported experiencing COVID-like symptoms (i.e., fever, cough, sore throat, difficulty
110 breathing, diarrhea, body pain, or loss of taste/smell) or within the last 7 days of their annual visits.
111 Additionally, an acute illness surveillance component was initiated via weekly text messages asking
112 participants to report if they or a household member experienced COVID-like symptoms in the past 7
113 days. Symptomatic participants, as well as those with a prior positive lab test for SARS-CoV-2 in the last
114 7-21 days and their household contacts, were offered visits for anterior nasal swab collection for SARS-

115 CoV-2 RT-PCR testing. Beginning in December 2020, concurrent collection of a second anterior nasal
116 swab for testing by the BinaxNOW COVID-19 Antigen Card test was offered to all participants with a
117 swab collected for SARS-CoV-2 RT-PCR testing. All nasal swabs were collected by study staff, and
118 BinaxNOW testing was performed within one hour of collection at the study site. Our analyses include
119 COPA participants who were tested for SARS-CoV-2 between December 2020 and May 2023 using both
120 BinaxNOW and RT-PCR assays. COPA participants may have been tested multiple times in the study
121 period, including during the same and separate illness or exposure events.

122 Established in May 2012, SEDSS is an active surveillance system that monitors acute febrile and
123 respiratory illnesses in two emergency departments in Ponce, Puerto Rico. In 2018, an additional site was
124 established in an emergency department in San Juan.²¹⁻²³ Patients were eligible for enrollment if they
125 demonstrated fever upon presentation or within the past week (oral temperature $\geq 38^{\circ}\text{C}$, axillary
126 temperature $\geq 38.5^{\circ}\text{C}$), or cough/dyspnea within the last 14 days (with or without fever). Nasopharyngeal
127 swabs collected at enrollment from participants in SEDSS were tested for SARS-CoV-2 using RT-PCR.
128 Two collection approaches were employed for BinaxNOW testing in one of the two participating
129 emergency departments: staff-collected and participant-collected (self-testing) anterior nasal swabs.
130 Participants underwent staff-collected, self-collected, or both staff- and self-collected anterior nasal
131 swabbing concurrently. Participants were provided with clear and simple instructions for self-collection
132 and testing, including applying drops to the test card, swabbing both nostrils, and following specific steps
133 for test card handling.²⁵ Our analyses included SEDSS participants in the San Juan or Ponce sites tested
134 for SARS-CoV-2 between January and April 2021 using both BinaxNOW and RT-PCR assays.

135 For both COPA and SEDSS, the RT-PCR assays used included the CDC Real-Time Reverse
136 Transcription PCR Panel for tests performed before December 2021 and the CDC Influenza SARS-CoV-
137 2 (Flu SC2) Multiplex Assay for tests performed December 2021 and later.^{19,20}

138

139 *Statistical Analysis*

140 We reported frequencies of demographic characteristics (age group, sex, ethnicity, race, and
141 Hispanic/Latino), reported chronic medical conditions, COVID-19 vaccine doses, and number of RT-
142 PCR/BinaxNOW tests among all COPA and SEDSS participants with one or more RT-PCR/BinaxNOW
143 test result data available.

144 Using the SARS-CoV-2 RT-PCR result as our reference standard, we calculated measures of
145 diagnostic accuracy of BinaxNOW tests including sensitivity, specificity, positive predictive value,
146 negative predictive value, positive likelihood ratio, negative likelihood ratio, and the number needed to
147 diagnose (NND) of BinaxNOW tests compared to RT-PCR tests. Definitions of these measures are given
148 in Table S1. We calculated 95% confidence intervals (CI) for all measures. We used McNemar's test to
149 evaluate differences in proportions of discordant pairs (i.e., the differences between false positives and
150 false negatives) between BinaxNOW and the reference standard, RT-PCR.²⁶ It helps determine if one test
151 is more likely to produce false positives or false negatives compared to the other. To assess
152 discrimination, we calculated the area under the receiver operating characteristic curve (AUC-ROC).
153 AUC-ROC summarizes the trade-off between sensitivity and specificity, where an AUC of 1 indicates
154 perfect discrimination, and 0.5 indicates no discrimination.

155 We evaluated the performance of BinaxNOW compared to RT-PCR overall across all participants
156 as well as by days post symptom onset (0, 1–3, 4–6, 7+ days), symptom status (asymptomatic,
157 symptomatic), collection strategy (staff-collected, self-collected), number of COVID-19 vaccine doses
158 received prior to testing (0, 1, 2, 3 doses), primary SARS-CoV-2 variant (pre-Delta, Delta, Omicron)
159 circulating at time of sample collection, and Ct values of positive RT-PCR tests (≤ 25 , 26–30, 31–35, 36–
160 40). The classification of primary circulating SARS-CoV-2 variant was based on the time period from
161 their earliest detection in Puerto Rico until the detection of a new major variant: pre-Delta (cases through
162 May 31, 2021), Delta (June 1 to November 30, 2021), and Omicron (after December 1, 2021).²⁷

163 For COPA participants with repeated tests, we evaluated BinaxNOW performance for their initial
164 test as well as the repeated test 7–14 days after the initial test. We further stratified this analysis by
165 participant symptom status for the initial and repeated tests. We performed a sensitivity analysis for the

166 repeated tests by restricting to participants who had testing within 6 days of symptom onset to ensure the
167 repeated test was not for a different infection. For repeated tests among COPA participants, tests
168 separated by ≥ 90 days were considered as part of separate illness episodes, and tests within 7–14 days of
169 each other were considered part of the same illness episode.²⁸ The few COPA participant tests performed
170 between 15–89 days of another test were excluded from the analysis. In SEDSS, when both self-collected
171 and hospital staff-collected swabs were tested, all tests, including the RT-PCR test, were conducted on the
172 same day and included in the analyses.

173 We fit cubic splines to further understand the relationships between sensitivity and specificity of
174 BinaxNOW by days post onset of symptoms and total number of symptoms. All analyses were done using
175 R software, version 4.3.1 (R Foundation for Statistical Computing, Vienna, Austria).

176

177 **Results**

178 There were 1,207 total participants with results from paired BinaxNOW and RT-PCR tests: 943
179 (78.1%) from COPA and 264 (21.9%) from SEDSS (Table 1). The median age of all participants was 36
180 years (IQR: 17, 49), 57.4% were female, 99.7% were Hispanic/Latino, and 56.3% had reported past
181 diagnosis with one or more chronic medical conditions. Of 799 COPA participants with available
182 COVID-19 vaccine data, 92.5% had received at least two doses, whereas 5.8% remained unvaccinated.
183 All SEDSS participants were unvaccinated and tested before vaccines became widely available in Puerto
184 Rico. Among the 264 SEDSS participants, 58 (22.0%) underwent both staff-collected/tested and
185 participant-collected/tested BinaxNOW tests, resulting in a total of 322 BinaxNOW tests. In COPA, there
186 were 1,208 BinaxNOW tests from the 943 participants from December 2020 to May 2023. Of the 1,530
187 total tests from SEDSS and COPA, 404 (26.4%) were positive for SARS-CoV-2 on the BinaxNOW test
188 and 465 (30.4%) were positive by RT-PCR.

189 Across all participants (n=1,530 paired tests), the overall sensitivity of BinaxNOW compared to
190 RT-PCR was 84.1% (95% CI: 80.4%–87.3%), specificity was 98.8% (95% CI: 97.9%–99.3%), positive
191 predictive value was 96.8% (95% CI: 94.6%–98.3%), and negative predictive value was 93.4% (95% CI:

192 91.8%–94.8%) (Table 2). We further examined the diagnostic performance at different time intervals
193 following symptom onset. Sensitivities at 1–3 days post onset (92.1%) and 4–6 days post onset (94.2%)
194 were significantly higher than at ≥ 7 days post onset (70.2%) ($p < 0.001$). Specificity remained consistently
195 above 98% across all days post-onset. The sensitivity of the BinaxNOW test peaked between 1 and 6 days
196 post-onset and waned thereafter (Figure 1).

197 The sensitivity of BinaxNOW was higher for symptomatic (86.3%) than for asymptomatic
198 (67.3%) participants, whereas specificity estimates were the same (98.8%) for both groups. Sensitivity did
199 not significantly vary by the number of symptoms reported (Figure S1). For symptomatic participants,
200 one correct diagnosis was obtained for every 1.2 patients tested with BinaxNOW on average during the
201 study period (NND = 1.2, 95% CI: 1.1–1.2) (Table 3). For asymptomatic participants, one correct
202 diagnosis was obtained for every 1.5 patients tested with BinaxNOW on average during the study period
203 (NND = 1.5, 95% CI: 1.3–2.0). The sensitivity and specificity of BinaxNOW showed consistent
204 performance across participants regardless of the number of COVID-19 vaccine doses received, with
205 overlapping confidence intervals for all groups (Table 2).

206 We evaluated the diagnostic performance of BinaxNOW using swabs collected and tested by
207 participants, as well as those collected and tested by study staff. BinaxNOW testing of self-collected and
208 staff-collected anterior nasal swabs from SEDSS showed sensitivities of 85.2% and 79.3%, respectively,
209 and 100% specificity (Table 2). BinaxNOW testing of staff-collected anterior nasal swabs from COPA
210 had 84.3% sensitivity and 98.4% specificity. BinaxNOW tests in anterior nasal swabs collected by both
211 participants (AUC-ROC = 0.926) and staff (AUC-ROC = 0.913) showed a strong ability to discriminate
212 between true positives and true negatives (Table 3). Among individuals positive by RT-PCR, SEDSS
213 participants had lower median Ct values (23, IQR: 21–30) compared to symptomatic COPA participants
214 (27, IQR: 23–31) ($p = 0.004$) and a higher median number of symptoms (9, IQR: 5–12) compared to
215 symptomatic COPA participants (1, IQR: 1–1) ($p < 0.001$). In the COPA cohort, sensitivity was 55.4%
216 (95% CI: 44.1%–66.3%) for 83 positive RT-PCR tests from asymptomatic participants and 86.8% (95%
217 CI: 82.8%–90.1%) for 355 positive RT-PCRs from symptomatic participants (Figure S2).

218 There were 184 participants who had repeated tests within a single illness or exposure event (7–
219 14 days after the initial test). In the initial test, BinaxNOW demonstrated high sensitivity (96.3%) and
220 specificity (96.0%) for detecting SARS-CoV-2 (Table 2). During subsequent sample collection and
221 testing 7–14 days later, sensitivity decreased to 48.4%, while specificity remained high at 97.9% (*p*-value
222 from McNemar’s test < 0.001). Restricting to 134 participants who had the initial test within 6 days of
223 symptom onset, the sensitivity was 96.1% for the initial test and 48.8% for the repeated test 7–14 days
224 later. The initial test showed strong overall performance (AUC-ROC = 0.961), whereas the follow-up
225 testing showed a decline in accuracy for identifying positive cases over time (AUC-ROC = 0.731) (Table
226 3). Sensitivity dropped significantly for participants initially symptomatic (98.7%) and later
227 asymptomatic (23.1%) (Figure 2, Table S2). Conversely, sensitivity increased for those initially
228 asymptomatic (50.0%) and later symptomatic (100%), but this difference was not statistically significant
229 possibly due to the limited sample size.

230 The sensitivity of BinaxNOW varied significantly depending on the Ct values from positive RT-
231 PCR tests. For Ct values ≤ 25 , paired BinaxNOW tests showed 99.5% sensitivity in correctly identifying
232 positive cases (Table 4). Conversely, as Ct values increased, test accuracy declined, reaching only 18.2%
233 for Ct values between 36–40.

234

235 **Discussion**

236 Our results demonstrated an overall 84.1% sensitivity for the Abbot BinaxNOW COVID-19
237 Antigen Card Test which falls within the upper range of previously reported BinaxNOW sensitivities
238 (50–85%) among other studies.^{11-14,29} The test also demonstrated high specificity (98.8%), positive
239 predictive value (96.8%), and negative predictive value (93.4%). Test sensitivity was highest 1–6 days
240 post onset and decreased significantly thereafter. These findings are in agreement with other studies,
241 highlighting the importance of timing in SARS-CoV-2 antigen testing.^{30,31}

242 Our findings regarding BinaxNOW test performance in symptomatic and asymptomatic
243 individuals also align with those from other studies,¹¹⁻¹⁴ showing substantially higher test sensitivity in

244 symptomatic compared to asymptomatic individuals, while maintaining a high level of specificity for
245 both groups. We did not find a clear dose-response relationship between the number of symptoms
246 experienced and sensitivity, but the point estimate for test sensitivity was highest (91.5%) among
247 participants with ten or more symptoms. Symptom type and indicators of disease severity, such as low
248 oxygen saturation levels, tachypnea, or requiring hospitalization, rather than simply the number of
249 symptoms reported, may have a greater influence on diagnostic accuracy.³² These results corroborate
250 previous research and highlight the challenges of detecting SARS-CoV-2 infections in asymptomatic
251 cases.¹¹⁻¹⁴ Clinicians should consider these factors and follow CDC guidelines for using antigen tests,
252 including repeat testing for asymptomatic individuals who were exposed, considering other etiologies for
253 symptomatic individuals, and repeating testing with RT-PCR in situations where sensitivity is of
254 paramount importance according to CDC recommendations.³³

255 Following infection, SARS-CoV-2 viral replication and shedding precede symptoms, with peak
256 viral titers occurring near the day of symptom onset and declining thereafter.³⁴ This trend is supported by
257 studies indicating that antigen testing demonstrates higher sensitivity early in infection when viral loads
258 are high, while repeated sampling over the illness course correlates with decreasing sensitivity.^{11,30,31,35,36}
259 Ct values from RT-PCR tests also provide quantity of viral genetic material in the sample (as an
260 approximate proxy for viral load) with increasing Ct values reflecting decreasing viral genetic
261 material.^{37,38} Our study used the same RT-PCR assay for SEDSS participants, but two different RT-PCR
262 assays were used in COPA, which precludes direct comparison of Ct values due to variation in sensitivity,
263 chemistry of reagents, gene targets, cycle parameters, and others.³⁷ BinaxNOW test showed peak
264 sensitivity (99.5%) when the Ct values of paired RT-PCR tests were 25 or lower, suggesting a higher
265 concentration of viral genetic material, typically indicative of early-stage infection. This is consistent with
266 our findings of reduced sensitivity 7 or more days after symptom onset, as well as those showing a
267 significant decline in sensitivity with repeated testing conducted in samples collected 7–14 days after
268 initial testing. These findings emphasize the importance of testing during the early infection stage and
269 maximizing the utility of isolation and treatment, when indicated. However, BinaxNOW test sensitivity

270 drops significantly (18.2%) for cases with Ct values between 36–40, suggesting a diminished capacity to
271 detect positive SARS-CoV-2 cases among individuals with lower viral genetic material concentrations
272 during later stages of infection.

273 Compared to ancestral variants, Delta and Omicron are characterized by their shorter incubation
274 periods, serial intervals, enhanced immune evasion, and heightened transmissibility.³⁹⁻⁴¹ Studies have
275 yielded mixed results in viral load patterns for these variants, with some reporting higher viral loads for
276 Delta,^{42,43} whereas others report higher viral loads for Omicron BA.1.^{44,45} The limited number of tests
277 during the Delta variant dominant period in our study precluded robust comparisons of sensitivity
278 between SARS-CoV-2 variants, and there were overlapping confidence intervals for sensitivity across the
279 variants. One study reported lower BinaxNOW COVID-19 Antigen test sensitivity for infections with the
280 Omicron variant compared to those with the Delta variant,⁴⁶ and another found no significant difference
281 in sensitivity between the two variants.⁴⁷ The impact of infection prevalence, such as the lower prevalence
282 in the Delta period, may have affected the results. Lower prevalence can lead to higher false-negative
283 rates as the proportion of true negatives in the population increases, influencing the balance of sensitivity
284 and specificity. Sensitivity and specificity of the BinaxNOW test remained consistent across participants
285 regardless of their COVID-19 vaccination status, similar to other studies.^{29,48}

286 Test timing, the patient’s clinical presentation, and the prevalence of SARS-CoV-2 infection in
287 the community should be considered when interpreting results and making diagnostic decisions. This
288 approach aligns with CDC guidance on COVID-19 testing.⁴⁹ Different settings require tailored testing
289 strategies. Healthcare settings attending to immunocompromised individuals may rely on highly sensitive
290 RT-PCR tests to accurately detect prolonged viral shedding. Conversely, antigen tests may provide
291 sufficient diagnostic accuracy in most settings, particularly when timely results are essential for public
292 health intervention or treatment.

293 Our study evaluated the performance of BinaxNOW COVID-19 Antigen test for both self-
294 collected and staff-collected anterior nasal swab samples. We observed high sensitivities (85.2% and
295 83.9%) and specificities (>98%) for both collection methods, consistent with the literature emphasizing

296 the feasibility and reliability of self-collection methods.^{50,51} Sensitivity among participants from the
297 hospital-based surveillance site (SEDSS) (83.1%) was not significantly different than among
298 symptomatic participants from the community-based cohort (COPA) (86.8%), but was significantly
299 higher than asymptomatic COPA participants (55.4%).

300 This study had several limitations. Our population was composed primarily of individuals that
301 identified as Hispanic/Latino and Puerto Rican between the ages of 0 and 50 years, which may not fully
302 represent diverse populations or epidemiological conditions found elsewhere. BinaxNOW performance
303 may vary in populations with different demographic characteristics, vaccination rates, or healthcare
304 access. Additionally, participants in our study, comprising individuals seeking medical attention or
305 enrolling in a community-based cohort study, may differ from non-participants regarding healthcare-
306 seeking behavior, symptom severity, proximity to healthcare facilities, access to healthcare,
307 socioeconomic factors, and risk perception, potentially introducing selection bias. Our study included pre-
308 Delta, Delta, and Omicron (time period covering BA.1 through XBB.1.5⁵²) variants. However, our study
309 population had low SARS-CoV-2 transmission prior to the Omicron variant. More recent Omicron
310 subvariants like EG.5 and FL.1.5.1 may have viral mutations that affect BinaxNOW performance.
311 Furthermore, our study used the dominant variant period as a proxy for the actual variant of the
312 individual, potentially misclassifying cases due to variability within these periods. Lastly, our study
313 focused on a rapid antigen test for SARS-CoV-2 from a single manufacturer. Our findings may not apply
314 to other antigen tests with potentially different performance characteristics.

315

316 **Conclusions**

317 Our study provides valuable insights into the diagnostic performance of BinaxNOW COVID-19
318 Antigen Card Test in different epidemiological contexts. While demonstrating high sensitivity and
319 specificity, our findings highlight the influence of factors such as symptomatology, viral load, and timing
320 of specimen collection on test accuracy. BinaxNOW remains a valuable tool for home use and early
321 infection identification, offering numerous advantages, including low cost, extended shelf life,

322 temperature stability, ease of use, and the ability to identify individuals with high viral loads. However,
323 its application should be considered alongside clinical and epidemiological context.³³ Future research
324 should continue to explore the evolving landscape of SARS-CoV-2 variants and the performance of rapid
325 antigen tests across diverse populations to further enhance our understanding and response to COVID-19.

326

327 **References**

- 328 1. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. October 12, 2023.
329 Accessed October 12, 2023. <https://covid19.who.int/>
- 330 2. Centers for Disease Control and Prevention. Isolation and Precautions for People with COVID-
331 19. October 3, 2023. Accessed October 3, 2023. [https://www.cdc.gov/coronavirus/2019-
332 ncov/your-health/isolation.html](https://www.cdc.gov/coronavirus/2019-
332 ncov/your-health/isolation.html)
- 333 3. Sah P, Fitzpatrick MC, Zimmer CF, et al. Asymptomatic SARS-CoV-2 infection: A systematic
334 review and meta-analysis. *Proc Natl Acad Sci U S A*. Aug 24
335 2021;118(34):doi:10.1073/pnas.2109229118
- 336 4. Wong JM, Volkman HR, Adams LE, et al. Clinical Features of COVID-19, Dengue, and
337 Influenza among Adults Presenting to Emergency Departments and Urgent Care Clinics-Puerto
338 Rico, 2012-2021. *Am J Trop Med Hyg*. Jan 11 2023;108(1):107-114. doi:10.4269/ajtmh.22-0149
- 339 5. Salama C, Han J, Yau L, et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. *N*
340 *Engl J Med*. Jan 7 2021;384(1):20-30. doi:10.1056/NEJMoa2030340
- 341 6. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk,
342 Nonhospitalized Adults with Covid-19. *N Engl J Med*. Apr 14 2022;386(15):1397-1408.
343 doi:10.1056/NEJMoa2118542
- 344 7. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for Oral Treatment of
345 Covid-19 in Nonhospitalized Patients. *N Engl J Med*. Feb 10 2022;386(6):509-520.
346 doi:10.1056/NEJMoa2116044
- 347 8. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final
348 Report. *N Engl J Med*. Nov 5 2020;383(19):1813-1826. doi:10.1056/NEJMoa2007764
- 349 9. Li Y, Yao L, Li J, et al. Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized
350 patients clinically diagnosed with COVID-19. *J Med Virol*. Jul 2020;92(7):903-908.
351 doi:10.1002/jmv.25786
- 352 10. Dinnes J, Deeks JJ, Berhane S, et al. Rapid, point-of-care antigen and molecular-based tests for
353 diagnosis of SARS-CoV-2 infection. *Cochrane Database Syst Rev*. Mar 24 2021;3(3):Cd013705.
354 doi:10.1002/14651858.CD013705.pub2
- 355 11. Prince-Guerra JL, Almendares O, Nolen LD, et al. Evaluation of Abbott BinaxNOW Rapid
356 Antigen Test for SARS-CoV-2 Infection at Two Community-Based Testing Sites - Pima County,
357 Arizona, November 3-17, 2020. *MMWR Morb Mortal Wkly Rep*. Jan 22 2021;70(3):100-105.
358 doi:10.15585/mmwr.mm7003e3
- 359 12. Siddiqui ZK, Chaudhary M, Robinson ML, et al. Implementation and Accuracy of BinaxNOW
360 Rapid Antigen COVID-19 Test in Asymptomatic and Symptomatic Populations in a High-
361 Volume Self-Referred Testing Site. *Microbiol Spectr*. Dec 22 2021;9(3):e0100821.
362 doi:10.1128/Spectrum.01008-21
- 363 13. Almendares O, Prince-Guerra JL, Nolen LD, et al. Performance Characteristics of the Abbott
364 BinaxNOW SARS-CoV-2 Antigen Test in Comparison to Real-Time Reverse Transcriptase PCR
365 and Viral Culture in Community Testing Sites during November 2020. *J Clin Microbiol*. Jan 19
366 2022;60(1):e0174221. doi:10.1128/JCM.01742-21

- 367 14. Sood N, Shetgiri R, Rodriguez A, et al. Evaluation of the Abbott BinaxNOW rapid antigen test
368 for SARS-CoV-2 infection in children: Implications for screening in a school setting. *PLoS One*.
369 2021;16(4):e0249710. doi:10.1371/journal.pone.0249710
- 370 15. Pilarowski G, Marquez C, Rubio L, et al. Field Performance and Public Health Response Using
371 the BinaxNOW™ Rapid Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
372 Antigen Detection Assay During Community-Based Testing. *Clin Infect Dis*. Nov 2
373 2021;73(9):e3098-e3101. doi:10.1093/cid/ciaa1890
- 374 16. Adams LE, Sánchez-González L, Rodríguez DM, et al. Risk factors for infection with
375 chikungunya and Zika viruses in southern Puerto Rico: A community-based cross-sectional
376 seroprevalence survey. *PLoS Negl Trop Dis*. Jun 2022;16(6):e0010416.
377 doi:10.1371/journal.pntd.0010416
- 378 17. Rodríguez DM, Ryff K, Sánchez-Gonzalez L, Rivera-Amill V, Paz-Bailey G, Adams L. HTrack:
379 A new tool to facilitate public health field visits and electronic data capture. *PLoS One*.
380 2020;15(12):e0244028. doi:10.1371/journal.pone.0244028
- 381 18. Sánchez-González L, Adams LE, Saavedra R, et al. Assessment of community support for
382 Wolbachia-mediated population suppression as a control method for *Aedes aegypti* mosquitoes in
383 a community cohort in Puerto Rico. *PLoS Negl Trop Dis*. Dec 2021;15(12):e0009966.
384 doi:10.1371/journal.pntd.0009966
- 385 19. Lu X, Wang L, Sakthivel SK, et al. US CDC Real-Time Reverse Transcription PCR Panel for
386 Detection of Severe Acute Respiratory Syndrome Coronavirus 2. *Emerg Infect Dis*. Aug
387 2020;26(8):1654-65. doi:10.3201/eid2608.201246
- 388 20. Centers for Disease Control and Prevention. CDC's Influenza SARS-CoV-2 Multiplex Assay.
389 November 9, 2023. Accessed November 9, 2023. <https://www.cdc.gov/coronavirus/2019-ncov/lab/multiplex.html>
- 390
391 21. Tomashek KM, Lorenzi OD, Andújar-Pérez DA, et al. Clinical and epidemiologic characteristics
392 of dengue and other etiologic agents among patients with acute febrile illness, Puerto Rico, 2012–
393 2015. *PLoS neglected tropical diseases*. 2017;11(9):e0005859.
- 394 22. Tomashek KM, Rivera A, Torres-Velasquez B, et al. Enhanced Surveillance for Fatal Dengue-
395 Like Acute Febrile Illness in Puerto Rico, 2010–2012. *PLoS Negl Trop Dis*. Oct
396 2016;10(10):e0005025. doi:10.1371/journal.pntd.0005025
- 397 23. Departamento de Salud Puerto Rico. Orden Administrativa Núm. 2021-496. September 26, 2023.
398 Accessed September 26, 2023. <https://www.salud.pr.gov/CMS/DOWNLOAD/3636>
- 399 24. ThermoFisher Scientific. TaqPath™ 1-Step RT-qPCR Master Mix, CG. November 8, 2023.
400 Accessed November 8, 2023. <https://www.thermofisher.com/order/catalog/product/A15299>
- 401 25. Abbott. BinaxNOW COVID-19 Antigen Test. October 12, 2023. Accessed October 12, 2023.
402 [https://www.globalpointofcare.abbott/us/en/product-details/binaxnow-covid-19-antigen-self-test-](https://www.globalpointofcare.abbott/us/en/product-details/binaxnow-covid-19-antigen-self-test-us.html)
403 [us.html](https://www.globalpointofcare.abbott/us/en/product-details/binaxnow-covid-19-antigen-self-test-us.html)
- 404 26. McNemar Q. Note on the sampling error of the difference between correlated proportions or
405 percentages. *Psychometrika*. 1947;12(2):153-157.
- 406 27. Santiago GA, Volkman HR, Flores B, et al. SARS-CoV-2 Omicron Replacement of Delta as
407 Predominant Variant, Puerto Rico. *Emerging Infectious Diseases*. 2023;29(4):855.
- 408 28. Centers for Disease Control and Prevention. Investigative Criteria for Suspected Cases of SARS-
409 CoV-2 Reinfection (ICR). September 8, 2023. Accessed September 8, 2023.
410 <https://stacks.cdc.gov/view/cdc/96072>
- 411 29. Schrom J, Marquez C, Petersen M, DeRisi J, Havlir D. Comparison of SARS-CoV-2 Reverse
412 Transcriptase Polymerase Chain Reaction and BinaxNOW Rapid Antigen Tests at a Community
413 Site During an Omicron Surge. *Ann Intern Med*. Oct 2022;175(10):W119. doi:10.7326/122-0257
- 414 30. Abusrewil Z, Alhudiri IM, Kaal HH, et al. Time scale performance of rapid antigen testing for
415 SARS-CoV-2: Evaluation of 10 rapid antigen assays. *J Med Virol*. Dec 2021;93(12):6512-6518.
416 doi:10.1002/jmv.27186

- 417 31. Chu VT, Schwartz NG, Donnelly MAP, et al. Comparison of Home Antigen Testing With RT-
418 PCR and Viral Culture During the Course of SARS-CoV-2 Infection. *JAMA Internal Medicine*.
419 2022;182(7):701-709. doi:10.1001/jamainternmed.2022.1827
- 420 32. Brihn A, Chang J, K OY, et al. Diagnostic Performance of an Antigen Test with RT-PCR for the
421 Detection of SARS-CoV-2 in a Hospital Setting - Los Angeles County, California, June-August
422 2020. *MMWR Morb Mortal Wkly Rep*. May 14 2021;70(19):702-706.
423 doi:10.15585/mmwr.mm7019a3
- 424 33. Centers for Disease Control and Prevention. Considerations for SARS-CoV-2 Antigen Testing for
425 Healthcare Providers Testing Individuals in the Community. September 27, 2023. Accessed
426 September 27, 2023. [https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-](https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html)
427 [guidelines.html](https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html)
- 428 34. Killingley B, Mann AJ, Kalinova M, et al. Safety, tolerability and viral kinetics during SARS-
429 CoV-2 human challenge in young adults. *Nat Med*. May 2022;28(5):1031-1041.
430 doi:10.1038/s41591-022-01780-9
- 431 35. Parvu V, Gary DS, Mann J, et al. Factors that Influence the Reported Sensitivity of Rapid
432 Antigen Testing for SARS-CoV-2. Original Research. *Frontiers in Microbiology*. 2021-October-
433 05 2021;12doi:10.3389/fmicb.2021.714242
- 434 36. Smith RL, Gibson LL, Martinez PP, et al. Longitudinal Assessment of Diagnostic Test
435 Performance Over the Course of Acute SARS-CoV-2 Infection. *J Infect Dis*. Sep 17
436 2021;224(6):976-982. doi:10.1093/infdis/jiab337
- 437 37. Public Health England. Understanding cycle threshold (Ct) in SARS-CoV-2 RT-PCR. November
438 8, 2023. Accessed November 8, 2023.
439 [https://assets.publishing.service.gov.uk/media/5f85c727d3bf7f633cfcdb1f/Understanding_Cycle_](https://assets.publishing.service.gov.uk/media/5f85c727d3bf7f633cfcdb1f/Understanding_Cycle_Threshold_Ct_in_SARS-CoV-2_RT-PCR_.pdf)
440 [Threshold_Ct_in_SARS-CoV-2_RT-PCR_.pdf](https://assets.publishing.service.gov.uk/media/5f85c727d3bf7f633cfcdb1f/Understanding_Cycle_Threshold_Ct_in_SARS-CoV-2_RT-PCR_.pdf)
- 441 38. Jaafar R, Aherfi S, Wurtz N, et al. Correlation Between 3790 Quantitative Polymerase Chain
442 Reaction-Positives Samples and Positive Cell Cultures, Including 1941 Severe Acute Respiratory
443 Syndrome Coronavirus 2 Isolates. *Clin Infect Dis*. Jun 1 2021;72(11):e921.
444 doi:10.1093/cid/ciaa1491
- 445 39. Madewell ZJ, Yang Y, Longini IM, Halloran ME, Vespignani A, Dean NE. Rapid review and
446 meta-analysis of serial intervals for SARS-CoV-2 Delta and Omicron variants. *BMC Infectious*
447 *Diseases*. 2023/06/26 2023;23(1):429. doi:10.1186/s12879-023-08407-5
- 448 40. Madewell ZJ, Yang Y, Longini IM, Jr., Halloran ME, Dean NE. Household Secondary Attack
449 Rates of SARS-CoV-2 by Variant and Vaccination Status: An Updated Systematic Review and
450 Meta-analysis. *JAMA Netw Open*. Apr 1 2022;5(4):e229317.
451 doi:10.1001/jamanetworkopen.2022.9317
- 452 41. Wu Y, Kang L, Guo Z, Liu J, Liu M, Liang W. Incubation Period of COVID-19 Caused by
453 Unique SARS-CoV-2 Strains: A Systematic Review and Meta-analysis. *JAMA Network Open*.
454 2022;5(8):e2228008-e2228008. doi:10.1001/jamanetworkopen.2022.28008
- 455 42. Puhach O, Meyer B, Eckerle I. SARS-CoV-2 viral load and shedding kinetics. *Nature Reviews*
456 *Microbiology*. 2023;21(3):147-161.
- 457 43. Yang Y, Guo L, Yuan J, et al. Viral and antibody dynamics of acute infection with SARS-CoV-2
458 omicron variant (B.1.1.529): a prospective cohort study from Shenzhen, China. *Lancet Microbe*.
459 Aug 2023;4(8):e632-e641. doi:10.1016/s2666-5247(23)00139-8
- 460 44. Kim JM, Kim D, Lee NJ, et al. Increased viral load in patients infected with severe acute
461 respiratory syndrome coronavirus 2 Omicron variant in the Republic of Korea. *Osong Public*
462 *Health Res Perspect*. Aug 2023;14(4):272-278. doi:10.24171/j.phrp.2023.0024
- 463 45. Granerud BK, Ueland T, Lind A, et al. Omicron Variant Generates a Higher and More Sustained
464 Viral Load in Nasopharynx and Saliva Than the Delta Variant of SARS-CoV-2. *Viruses*. Oct 31
465 2022;14(11)doi:10.3390/v14112420
- 466 46. Rao A, Westbrook A, Bassit L, et al. Sensitivity of Rapid Antigen Tests Against SARS-CoV-2
467 Omicron and Delta Variants. *medRxiv*. Feb 10 2023;doi:10.1101/2023.02.09.23285583

- 468 47. Soni A, Herbert C, Filippaios A, et al. Comparison of Rapid Antigen Tests' Performance Between
469 Delta and Omicron Variants of SARS-CoV-2 : A Secondary Analysis From a Serial Home Self-
470 testing Study. *Ann Intern Med.* Dec 2022;175(12):1685-1692. doi:10.7326/m22-0760
471 48. Murakami M, Sato H, Irie T, et al. Sensitivity of rapid antigen tests for COVID-19 during the
472 Omicron variant outbreak among players and staff members of the Japan Professional Football
473 League and clubs: a retrospective observational study. *BMJ Open.* Jan 30 2023;13(1):e067591.
474 doi:10.1136/bmjopen-2022-067591
475 49. Centers for Disease Control and Prevention. Overview of Testing for SARS-CoV-2, the virus that
476 causes COVID-19. September 27, 2023. Accessed September 27, 2023.
477 <https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html>
478 50. Stohr JJM, Zwart VF, Goderski G, et al. Self-testing for the detection of SARS-CoV-2 infection
479 with rapid antigen tests for people with suspected COVID-19 in the community. *Clinical*
480 *Microbiology and Infection.* 2022/05/01/ 2022;28(5):695-700.
481 doi:<https://doi.org/10.1016/j.cmi.2021.07.039>
482 51. Wöfl-Duchek M, Bergmann F, Jorda A, et al. Sensitivity and specificity of SARS-CoV-2 rapid
483 antigen detection tests using oral, anterior nasal, and nasopharyngeal swabs: a diagnostic
484 accuracy study. *Microbiology spectrum.* 2022;10(1):e02029-21.
485 52. Centers for Disease Control and Prevention. Variant Proportions. October 2, 2023. Accessed
486 October 2, 2023. <https://covid.cdc.gov/covid-data-tracker/>
487

488 **Figure Titles and Legends**

489 **Figure 1. Sensitivity and specificity of BinaxNOW Antigen test compared to RT-PCR by days post**
490 **onset of symptoms (N = 1181 paired tests from 921 participants with 0 to 16 days post onset).** The
491 blue line represents a cubic spline and grey bands indicate 95% confidence intervals of the model fit.
492 Vertical bars are 95% confidence intervals of BinaxNOW sensitivity and specificity for each days-post-
493 onset subgroup. There were 1181 tests of both BinaxNOW and RT-PCR.

494 **Figure 2. Sensitivity of BinaxNOW Antigen test compared to RT-PCR for initial tests and repeated**
495 **tests 7–14 days later by symptom status for the initial and repeated tests (N = 368 paired tests from**
496 **184 participants).** Additional diagnostic accuracy measures are shown in S2 Table. There were 368 tests
497 of both BinaxNOW and RT-PCR.

498

Table 1. Demographic characteristics of participants from COPA and SEDSS, 2020–2023.

	Overall N = 1207	COPA N = 943	SEDSS N = 264
Age in years (median [IQR])	36 [16, 49]	36 [16, 47]	36 [19, 58]
Age group in years (%) (N = 1207)			
0–10	149 (12.3)	96 (10.2)	53 (20.1)
11–20	222 (18.4)	208 (22.1)	14 (5.3)
21–30	146 (12.1)	102 (10.8)	44 (16.7)
31–40	180 (14.9)	142 (15.1)	38 (14.4)
41–50	263 (21.8)	237 (25.1)	26 (9.8)
51+	247 (20.5)	158 (16.8)	89 (33.7)
Sex (%) (N = 1206)			
Female	692 (57.4)	552 (58.6)	140 (53.0)
Male	514 (42.6)	390 (41.4)	124 (47.0)
Hispanic/Latino (%) (N = 1171)			
Yes	1168 (99.7)	912 (100.0)	256 (98.8)
No	3 (0.3)	0 (0)	3 (1.2)
Ethnicity (%) (N = 1170)			
Puerto Rican	1152 (98.5)	900 (98.8)	252 (97.3)
Other	18 (1.5)	11 (1.2)	7 (2.7)
Race (%) (N = 1118)			
Black	122 (10.9)	93 (10.4)	29 (12.9)
Mixed	101 (9.0)	85 (9.5)	16 (7.1)
White	849 (75.9)	685 (76.7)	164 (72.9)
Other	46 (4.1)	30 (3.4)	16 (7.1)
Chronic medical conditions (%) (N = 1205)			
Yes	679 (56.3)	531 (56.3)	148 (56.5)
No	526 (43.7)	412 (43.7)	114 (43.5)
COVID-19 vaccine doses recorded on final visit (%) (N = 1063)			
0	310 (29.2)	46 (5.8)	264 (100)
1	14 (1.5)	14 (1.8)	0 (0)
2	290 (30.5)	290 (36.3)	0 (0)
3	435 (45.7)	435 (54.4)	0 (0)
4	14 (1.5)	14 (1.8)	0 (0)
Symptomatic during study (%) (N = 1203)			
Yes	1030 (85.6)	770 (81.7)	260 (100)
No	173 (14.4)	173 (18.3)	0 (0)
Days from symptom onset to testing (median [IQR]) (N = 923)	4 [2, 6]	4 [3, 7]	2 [1, 4]
Number of RT-PCR/BinaxNOW tests (%) (N = 1207)			
1	733 (60.7)	527 (55.9)	206 (78.0)
2	318 (26.3)	260 (27.6)	58 (22.0) ^a
3	94 (7.8)	94 (10.0)	0 (0.0)
≥4	62 (5.1)	62 (6.6) ^b	0 (0.0)

IQR: interquartile range; COPA: Communities Organized to Prevent Arboviruses; SEDSS: Sentinel Enhanced Dengue Surveillance System; RT-PCR: reverse transcription polymerase chain reaction.

^a All repeat testing for SEDSS participants was performed on the same day with one swab collected by a healthcare provider and another self-collected swab.

^b For repeated tests among COPA participants, tests separated by ≥90 days were considered as part of separate illness episodes, and tests within 7–14 days of each other were considered part of the same illness episode. COPA participant tests performed between 15–89 days of another test were excluded from the analysis.

Table 2. Comparison of BinaxNOW and RT-PCR (N = 1530 paired^a tests from 1207 participants unless stated otherwise).

	True Positive, n (%)	True Negative, n (%)	False Positive, n (%)	False Negative, n (%)	Sensitivity % (95% CI)	Specificity % (95% CI)	Positive Predictive Value % (95% CI)	Negative Predictive Value % (95% CI)	McNemar's Chi Square P value ^b
Overall	391 (25.6)	1052 (68.8)	13 (0.8)	74 (4.8)	84.1 (80.4, 87.3)	98.8 (97.9, 99.3)	96.8 (94.6, 98.3)	93.4 (91.8, 94.8)	<0.001
Days post onset^c									
0	15 (20.0)	55 (73.3)	0 (0)	5 (6.7)	75.0 (50.9, 91.3)	100 (93.5, 100)	100 (78.2, 100)	91.7 (81.6, 97.2)	0.074
1–3	129 (26.9)	337 (70.2)	3 (0.6)	11 (2.3)	92.1 (86.4, 96.0)	99.1 (97.4, 99.8)	97.7 (93.5, 99.5)	96.8 (94.4, 98.4)	0.061
4–6	145 (40.4)	201 (56.0)	4 (1.1)	9 (2.5)	94.2 (89.2, 97.3)	98.0 (95.1, 99.5)	97.3 (93.3, 99.3)	95.7 (92.0, 98.0)	0.267
≥7	85 (30.6)	154 (55.4)	3 (1.1)	36 (12.9)	70.2 (61.3, 78.2)	98.1 (94.5, 99.6)	96.6 (90.4, 99.3)	81.1 (74.7, 86.4)	<0.001
Symptomatology^d									
Asymptomatic	37 (11.9)	252 (81.3)	3 (1.0)	18 (5.8)	67.3 (53.3, 79.3)	98.8 (96.6, 99.8)	92.5 (79.6, 98.4)	93.3 (89.7, 96.0)	0.002
≥1 symptom	353 (29.0)	797 (65.5)	10 (0.8)	56 (4.6)	86.3 (82.6, 89.5)	98.8 (97.7, 99.4)	97.2 (95.0, 98.7)	93.4 (91.6, 95.0)	<0.001
1–3 symptoms	266 (30.5)	556 (63.8)	9 (1.0)	41 (4.7)	86.6 (82.3, 90.2)	98.4 (97.0, 99.3)	96.7 (93.9, 98.5)	93.1 (90.8, 95.0)	<0.001
4–6 symptoms	24 (19.4)	92 (74.2)	0 (0)	8 (6.5)	75.0 (56.6, 88.5)	100 (96.1, 100)	100 (85.8, 100)	92.0 (84.8, 96.5)	0.013
7–9 symptoms	20 (19.4)	80 (77.7)	0 (0)	3 (2.9)	87.0 (66.4, 97.2)	100 (95.5, 100)	100 (83.2, 100)	96.4 (89.8, 99.2)	0.248
≥10 symptoms	43 (36.8)	69 (59.0)	1 (0.9)	4 (3.4)	91.5 (79.6, 97.6)	98.6 (92.3, 100)	97.7 (88.0, 99.9)	94.5 (86.6, 98.5)	0.371
Collection strategy									
Self, SEDSS	46 (34.3)	80 (59.7)	0 (0)	8 (6.0)	85.2 (72.9, 93.4)	100 (95.5, 100)	100 (92.3, 100)	90.9 (82.9, 96.0)	0.013
Staff, SEDSS	23 (12.2)	159 (84.6)	0 (0)	6 (3.2)	79.3 (60.3, 92.0)	100 (97.7, 100)	100 (85.2, 100)	96.4 (92.3, 98.7)	0.041
Self + Staff, SEDSS	69 (21.4)	239 (74.2)	0 (0)	14 (4.3)	83.1 (73.3, 90.5)	100 (98.5, 100)	100 (94.8, 100)	94.5 (90.9, 96.9)	0.001
Staff, COPA	322 (26.7)	813 (67.3)	13 (1.1)	60 (5.0)	84.3 (80.2, 87.8)	98.4 (97.3, 99.2)	96.1 (93.5, 97.9)	93.1 (91.2, 94.7)	<0.001
Staff, SEDSS + COPA	345 (24.7)	972 (69.6)	13 (0.9)	66 (4.7)	83.9 (80.0, 87.4)	98.7 (97.8, 99.3)	96.4 (93.9, 98.1)	93.6 (92.0, 95.0)	<0.001
Repeated tests^e									
Initial test	105 (57.1)	72 (39.1)	3 (1.6)	4 (2.2)	96.3 (90.9, 99.0)	96.0 (88.8, 99.2)	97.2 (92.1, 99.4)	94.7 (87.1, 98.5)	1
Repeated test 7–14 days after initial test	29 (15.8)	122 (66.3)	3 (1.6)	30 (16.3)	49.2 (35.9, 62.5)	97.6 (93.1, 99.5)	90.6 (75.0, 98.0)	80.3 (73.0, 86.3)	<0.001
Number of vaccine doses^f									
Unvaccinated	99 (19.9)	378 (75.9)	0 (0)	21 (4.2)	82.5 (74.5, 88.8)	100 (99.0, 100)	100 (96.3, 100)	94.7 (92.1, 96.7)	<0.001
1 dose	7 (16.3)	33 (76.7)	1 (2.3)	2 (4.7)	77.8 (40.0, 97.2)	97.1 (84.7, 99.9)	87.5 (47.3, 99.7)	94.3 (80.8, 99.3)	1
2 doses	100 (22.9)	310 (71.1)	2 (0.5)	24 (5.5)	80.6 (72.6, 87.2)	99.4 (97.7, 99.9)	98.0 (93.1, 99.8)	92.8 (89.5, 95.3)	<0.001
3 doses	144 (38.6)	201 (53.9)	8 (2.1)	20 (5.4)	87.8 (81.8, 92.4)	96.2 (92.6, 98.3)	94.7 (89.9, 97.7)	91.0 (86.4, 94.4)	0.038
4 doses	2 (22.2)	6 (66.7)	1 (11.1)	0 (0)	100 (15.8, 100)	85.7 (42.1, 99.6)	66.7 (9.4, 99.2)	100 (54.1, 100)	1
Predominant SARS-CoV-2 variant									
Pre-Delta	80 (16.7)	379 (79.1)	0 (0)	20 (4.2)	80.0 (70.8, 87.3)	100 (99.0, 100)	100 (95.5, 100)	95.0 (92.4, 96.9)	<0.001
Delta	7 (4.2)	156 (94.0)	0 (0)	3 (1.8)	70.0 (34.8, 93.3)	100 (97.7, 100)	100 (59.0, 100)	98.1 (94.6, 99.6)	0.248
Omicron	304 (34.4)	517 (58.4)	13 (1.5)	51 (5.8)	85.6 (81.5, 89.1)	97.5 (95.8, 98.7)	95.9 (93.1, 97.8)	91.0 (88.4, 93.2)	<0.001

RT-PCR: reverse transcription polymerase chain reaction; CI: confidence interval

^a There were 1530 tests of both BinaxNOW and RT-PCR.

^b We used McNemar's test to evaluate differences in proportions of discordant pairs (i.e., the differences between false positives and false negatives) between BinaxNOW and the reference standard, RT-PCR. It helps determine if one test is more likely to produce false positives or false negatives compared to the other.

^c N = 1192 tests from 923 participants—284 participants were missing symptom onset dates.

^d N = 1526 tests from 1203 participants—4 participants were missing symptom data. Symptoms included tiredness, cough, loss of smell, dyspnea, myalgia, throat pain, chest pain, nausea/vomiting, diarrhea, abdominal pain, nasal congestion, chills, conjunctivitis, skin changes, rash, arthralgia, eye pain, bleeding, irritability, and calf pain.

^e N = 368 tests from 184 participants. Restricted to participants who had repeated tests.

^f N = 1359 tests from 1063 participants—144 participants were missing vaccination data.

Table 3. Performance of BinaxNOW compared to RT-PCR (N = 1530 paired^a tests from 1207 participants unless stated otherwise).

	Positive likelihood ratio (95% CI)	Negative likelihood ratio (95% CI)	Correctly classified proportion (95% CI)	Apparent positivity (95% CI)	True positivity (95% CI)	Number needed to diagnose (95% CI)	AUC-ROC
Overall	68.89 (40.07, 118.41)	0.16 (0.13, 0.20)	0.943 (0.930, 0.954)	0.264 (0.242, 0.287)	0.304 (0.281, 0.328)	1.2 (1.2, 1.3)	0.914
Days post onset^b							
0	Inf	0.25 (0.12, 0.53)	0.933 (0.851, 0.978)	0.200 (0.116, 0.308)	0.267 (0.171, 0.381)	1.3 (1.1, 2.3)	0.875
1–3	104.43 (33.81, 322.51)	0.08 (0.04, 0.14)	0.971 (0.952, 0.984)	0.275 (0.236, 0.317)	0.292 (0.251, 0.335)	1.1 (1.0, 1.2)	0.956
4–6	48.25 (18.27, 127.44)	0.06 (0.03, 0.11)	0.964 (0.939, 0.981)	0.415 (0.364, 0.468)	0.429 (0.377, 0.482)	1.1 (1.0, 1.2)	0.961
≥7	36.76 (11.91, 113.43)	0.30 (0.23, 0.40)	0.860 (0.813, 0.898)	0.317 (0.262, 0.375)	0.435 (0.376, 0.496)	1.5 (1.3, 1.8)	0.842
Symptomatology^c							
Asymptomatic	57.18 (18.29, 178.78)	0.33 (0.23, 0.48)	0.932 (0.898, 0.958)	0.129 (0.094, 0.172)	0.177 (0.137, 0.225)	1.5 (1.3, 2.0)	0.830
≥1 symptom	69.65 (37.58, 129.11)	0.14 (0.11, 0.18)	0.946 (0.931, 0.958)	0.299 (0.273, 0.325)	0.336 (0.310, 0.364)	1.2 (1.1, 1.2)	0.925
1–3 symptoms	54.39 (28.41, 104.15)	0.14 (0.10, 0.18)	0.943 (0.925, 0.957)	0.315 (0.285, 0.347)	0.352 (0.320, 0.385)	1.2 (1.1, 1.3)	0.925
4–6 symptoms	Inf	0.25 (0.14, 0.46)	0.935 (0.877, 0.972)	0.194 (0.128, 0.274)	0.258 (0.184, 0.344)	1.3 (1.1, 1.9)	0.875
7–9 symptoms	Inf	0.13 (0.05, 0.37)	0.971 (0.917, 0.994)	0.194 (0.123, 0.284)	0.223 (0.147, 0.316)	1.2 (1.0, 1.6)	0.935
≥10 symptoms	64.04 (9.13, 449.18)	0.09 (0.03, 0.22)	0.957 (0.903, 0.986)	0.376 (0.288, 0.470)	0.402 (0.312, 0.496)	1.1 (1.0, 1.4)	0.950
Collection strategy							
Self, SEDSS	Inf	0.15 (0.08, 0.28)	0.940 (0.886, 0.974)	0.343 (0.263, 0.430)	0.403 (0.319, 0.491)	1.2 (1.1, 1.5)	0.926
Staff, SEDSS	Inf	0.21 (0.10, 0.42)	0.968 (0.932, 0.988)	0.122 (0.079, 0.178)	0.154 (0.106, 0.214)	1.3 (1.1, 1.7)	0.897
Self + Staff, SEDSS	Inf	0.17 (0.10, 0.27)	0.957 (0.928, 0.976)	0.214 (0.171, 0.263)	0.258 (0.211, 0.309)	1.2 (1.1, 1.4)	0.916
Staff, COPA	53.56 (31.18, 92.00)	0.16 (0.13, 0.20)	0.940 (0.925, 0.952)	0.277 (0.252, 0.303)	0.316 (0.290, 0.343)	1.2 (1.2, 1.3)	0.914
Staff, SEDSS + COPA	63.60 (37.00, 109.32)	0.16 (0.13, 0.20)	0.943 (0.930, 0.955)	0.256 (0.234, 0.280)	0.294 (0.271, 0.319)	1.2 (1.2, 1.3)	0.913
Repeated tests^d							
Initial test	24.08 (7.94, 73.03)	0.04 (0.01, 0.10)	0.962 (0.923, 0.985)	0.587 (0.512, 0.659)	0.592 (0.518, 0.664)	1.1 (1.0, 1.3)	0.961
Repeated test 7–14 days after initial test	20.48 (6.50, 64.53)	0.52 (0.40, 0.67)	0.821 (0.757, 0.873)	0.174 (0.122, 0.237)	0.321 (0.254, 0.393)	2.1 (1.6, 3.4)	0.734
Number of vaccine doses^e							
Unvaccinated	Inf	0.18 (0.12, 0.26)	0.958 (0.936, 0.974)	0.199 (0.165, 0.237)	0.241 (0.204, 0.281)	1.2 (1.1, 1.4)	0.913
1 dose	26.44 (3.72, 188.16)	0.23 (0.07, 0.78)	0.930 (0.809, 0.985)	0.186 (0.084, 0.334)	0.209 (0.100, 0.360)	1.3 (1.0, 4.1)	0.874
2 doses	125.81 (31.52, 502.14)	0.19 (0.14, 0.28)	0.940 (0.914, 0.961)	0.234 (0.195, 0.277)	0.284 (0.242, 0.329)	1.2 (1.1, 1.4)	0.900
3 doses	22.94 (11.60, 45.37)	0.13 (0.08, 0.19)	0.925 (0.893, 0.950)	0.408 (0.357, 0.459)	0.440 (0.389, 0.492)	1.2 (1.1, 1.3)	0.920
4 doses	7.00 (1.14, 42.97)	0.00 (0.00, 0.00)	0.889 (0.518, 0.997)	0.333 (0.075, 0.701)	0.222 (0.028, 0.600)	1.2 (-2.4, 1.0)	0.929
Predominant SARS-CoV-2 variant							
Pre-Delta	Inf	0.20 (0.14, 0.30)	0.958 (0.936, 0.974)	0.167 (0.135, 0.203)	0.209 (0.173, 0.248)	1.2 (1.1, 1.4)	0.900
Delta	Inf	0.30 (0.12, 0.77)	0.982 (0.948, 0.996)	0.042 (0.017, 0.085)	0.060 (0.029, 0.108)	1.4 (1.1, 3.1)	0.850
Omicron	34.91 (20.37, 59.82)	0.15 (0.11, 0.19)	0.928 (0.909, 0.944)	0.358 (0.327, 0.391)	0.401 (0.369, 0.434)	1.2 (1.1, 1.3)	0.916

RT-PCR: reverse transcription polymerase chain reaction; CI: confidence interval; AUC-ROC: Area Under the Receiver Operating Characteristic Curve

^a There were 1530 tests of both BinaxNOW and RT-PCR.

^b N = 1192 tests from 923 participants—284 participants were missing symptom onset dates.

^c N = 1526 tests from 1203 participants—4 participants were missing symptom data. Symptoms included tiredness, cough, loss of smell, dyspnea, myalgia, throat pain, chest pain, nausea/vomiting, diarrhea, abdominal pain, nasal congestion, chills, conjunctivitis, skin changes, rash, arthralgia, eye pain, bleeding, irritability, and calf pain.

^d N = 368 tests from 184 participants. Restricted to participants who had repeated tests.

^e N = 1359 tests from 1063 participants—144 participants were missing vaccination data.

Table 4. Sensitivity of BinaxNOW by Ct values of RT-PCR tests (N = 464 paired^a tests from 435 participants).

Ct value	Positive PCR tests N	Positive BinaxNOW tests N (%)	Negative BinaxNOW tests N (%)
≤25	198	197 (99.5)	1 (0.5)
26–30	121	113 (93.4)	8 (6.6)
31–35	101	72 (71.3)	29 (28.7)
36–40	44	8 (18.2)	36 (81.8)



RT-PCR: reverse transcription polymerase chain reaction.

^a This table includes positive RT-PCR tests and corresponding BinaxNOW test results. Of 465 total positive RT-PCR tests, 1 was missing a Ct value, therefore the sample size includes 464 tests of both BinaxNOW and RT-PCR.

502

Sensitivity

Specificity



Days Post Onset

